Monoclonal antibodies in cancer therapy, future outlook, present situation. The topic is approached via a literature review article to give the reader a good overview. The report is based on online database research via PubMed, Cochrane Library, Google Scholar, and ScienceDirect. The purpose of this article is to evaluate the role of antibodies in immunology and their possibilities and limitations in cancer diagnosis and treatment. The references were chosen with regard to their relevance and actuality regarding the discussed topic. Mesh search was used, and further information regarding research tactics is provided in the methodology. In this article, we did shine a light on different aspects of monoclonal antibody usage and the general principles of this novel therapeutic approach. The general mechanism, as well as pharmaceutical preparations, are discussed. This approach lets this work present solid basics of the theoretical and practical considerations, pathways, as well as benefits and risks of monoclonal therapeutics. More research in the future could provide even more promising results and provide ways to lower mortality from cancer and, eventually, other diseases.
Table of Contents
1. Abstract
2. Introduction
3. Body
3.1 Basics of Immunology
3.1.1 Immunity and components of the immune system
3.1.2 Cells of the immune system
3.1.3 Cytokines
3.1.4 Recognition of microbes/pathogens
3.1.5 Phagocytosis, Opsonization and the complement system
3.1.6 Antigenicity and Immunogenicity
3.1.7 Cluster of differentiation
3.1.8 Major Histocompatibility Complex (MHC)
3.2 Antibodies
3.2.1 Antibody structure
3.2.2 Action of antibodies
3.2.3 Antibody classification and properties
4. Clinical implication and discussion
5. Results
6. Methodology
Objectives and Research Themes
This thesis examines the fundamental immunological mechanisms underlying antibody function and evaluates the clinical utility, possibilities, and limitations of monoclonal antibodies in modern cancer diagnostics and therapeutics.
- Theoretical foundations of the human immune system and antigen recognition.
- Molecular structure and biological classification of immunoglobulins.
- Methodologies for the production and optimization of monoclonal antibodies.
- Clinical applications and therapeutic strategies in oncology, including antibody-drug conjugates (ADCs).
- Identification of resistance mechanisms and limitations in monoclonal antibody therapy.
Excerpt from the Book
Clinical implication and discussion
Multiple clones of the same cells are where polyclonal antibodies are derived from. It consists of a diverse range of binding sites. The use of polyclonal antibodies in diagnosis is highly beneficial. Antigens can be found and identified, as well as purified and characterized, thanks to the specific antigen-antibody interaction. The low concentrations, potential for cross-reactions, and consequently reduced specificity and sensitivity of polyclonal antibodies are drawbacks when used in medical practice.
Clones of a single activated B cell are used to create monoclonal antibodies. They are capable of identifying a single unique epitope on an antigen. They have the same specificity and are identical antibodies. Hybridoma Technology, also known as the method for making monoclonal antibodies, was developed in 1975 by G J F Koehler and Caesar Milstein.
Monoclonal antibodies found their role in immunotherapy, especially making great efforts in providing better treatment options for patients suffering from cancer.
Summary of Chapters
Abstract: Provides an overview of the role of monoclonal antibodies in cancer therapy and summarizes the research objectives and methodology.
Introduction: Explores the historical context of immunology and introduces monoclonal antibodies as a revolutionary tool in personalized medicine for cancer treatment.
Body: Details the complex components of the innate and adaptive immune system, the structure/function of antibodies, and the mechanism of monoclonal antibody production and application.
Clinical implication and discussion: Compares polyclonal and monoclonal antibodies and discusses the therapeutic subclasses and constraints of monoclonal antibody treatments.
Results: Synthesizes the core findings regarding the efficacy and mechanism of monoclonal therapeutic approaches in clinical settings.
Methodology: Describes the literature review process, including the evaluation of databases such as PubMed, Cochrane Library, and Google Scholar to assess current research standards.
Keywords
Monoclonal antibodies, Cancer therapy, Immunology, Immunoglobulins, Antibody-drug conjugates, Clinical oncology, Antigenicity, Hybridoma technology, Targeted therapy, Immune system, Pathogen recognition, Personalized medicine.
Frequently Asked Questions
What is the primary focus of this thesis?
The work focuses on evaluating the role of antibodies within immunology and their strategic application in the diagnosis and treatment of various types of cancer.
What are the central themes discussed?
The core themes include fundamental immunology, antibody structure and classification, the specific production process of monoclonal antibodies, and their clinical efficacy against malignant tumors.
What is the ultimate research objective?
The goal is to determine how immunoglobulins can be utilized to redirect the body’s immune system to identify and neutralize cancer cells through specific signaling pathways.
Which scientific methodology was employed?
The research is based on a systematic literature review, utilizing mesh search terms across major databases like PubMed, Cochrane Library, and ScienceDirect for the period of 2010 to 2022.
What is covered in the main body section?
It provides a comprehensive analysis ranging from the "Basics of Immunology," such as cell types and the complement system, to the specific structural properties and actions of different antibody classes.
Which keywords define this work?
Key terms include monoclonal antibodies, cancer therapy, immunotherapy, and antibody-drug conjugates (ADCs).
How does monoclonal antibody therapy differ from conventional treatments?
Unlike non-specific therapies, monoclonal antibodies are designed to recognize and target specific antigens on cancer cells, effectively hijacking their own immune mechanisms to facilitate tumor cell destruction.
What limitations does monoclonal antibody therapy face according to the document?
The efficacy is largely dependent on the availability of target molecules on the tumor; mutations that downregulate these proteins can result in treatment resistance and reduced therapeutic impact.
- Quote paper
- Anonym (Author), 2022, The role of antibodies in cancer treatment and diagnosis, Munich, GRIN Verlag, https://www.grin.com/document/1326095
